Vernalis Plc - Product Pipeline Review – 2015 Is Released Vernalis Plc - Product Pipeline Review - 2015 Summary Global Markets Direct s, Vernalis plc - Product Pipeline Review - 2015, provides an overview of the Vernalis plc s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Vernalis plcs, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Vernalis plc including business description, key information and facts, and its locations and subsidiaries The report reviews current pipeline of Vernalis plcs human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Vernalis plcs pipeline products Reasons to buy - Evaluate Vernalis plcs strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Vernalis plc in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Vernalis plcs R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Vernalis plc and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vernalis plc - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Vernalis plc and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues 1
Browse Complete Report with TOC http://www.idatainsights.com/reports-landingpage.php?id=179162/vernalis-plc-product-pipeline-review-2015 To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landingpage.php?id=179162/vernalis-plc-product-pipeline-review-2015 Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Vernalis Plc Snapshot 5 Vernalis Plc Overview 5 Key Information 5 Key Facts 5 Vernalis Plc - Research and Development Overview 6 Key Therapeutic Areas 6 Vernalis Plc - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Vernalis Plc - Pipeline Products Glance 14 Vernalis Plc - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Vernalis Plc - Early Stage Pipeline Products 15
2
Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 Vernalis Plc - Unknown Stage Pipeline Products 17 Unknown Products/Combination Treatment Modalities 17 Vernalis Plc - Drug Profiles 18 V-81444 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 CCP-05 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 CCP-06 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 V-158411 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 vipadenant 22 Product Description 22 Mechanism of Action 22 3
R&D Progress 22 Small Molecule to Inhibit Chk1 for Cancer 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 CCP-07 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 CCP-08 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Vernalis Plc - Pipeline Analysis 26 Vernalis Plc - Pipeline Products by Target 26 Vernalis Plc - Pipeline Products by Route of Administration 27 Vernalis Plc - Pipeline Products by Molecule Type 28 Vernalis Plc - Pipeline Products by Mechanism of Action 29 Vernalis Plc - Recent Pipeline Updates 30 Vernalis Plc - Dormant Projects 32 Vernalis Plc - Discontinued Pipeline Products 33 Discontinued Pipeline Product Profiles 33 alfadolone 33 4
indantadol 33 marimastat 33 solimastat 33 V-1003 33 V-158866 34 vipadenant 34 Vernalis Plc - Company Statement 35 Vernalis Plc - Locations And Subsidiaries 37 Head Office 37 Other Locations & Subsidiaries 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 38 Disclaimer 39" width="80" height="40" />Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Vernalis Plc Snapshot 5 Vernalis Plc Overview 5 Key Information 5 5
Key Facts 5 Vernalis Plc - Research and Development Overview 6 Key Therapeutic Areas 6 Vernalis Plc - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Vernalis Plc - Pipeline Products Glance 14 Vernalis Plc - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Vernalis Plc - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 Vernalis Plc - Unknown Stage Pipeline Products 17 Unknown Products/Combination Treatment Modalities 17 Vernalis Plc - Drug Profiles 18 V-81444 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 6
CCP-05 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 CCP-06 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 V-158411 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 vipadenant 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Small Molecule to Inhibit Chk1 for Cancer 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 CCP-07 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 7
CCP-08 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Vernalis Plc - Pipeline Analysis 26 Vernalis Plc - Pipeline Products by Target 26 Vernalis Plc - Pipeline Products by Route of Administration 27 Vernalis Plc - Pipeline Products by Molecule Type 28 Vernalis Plc - Pipeline Products by Mechanism of Action 29 Vernalis Plc - Recent Pipeline Updates 30 Vernalis Plc - Dormant Projects 32 Vernalis Plc - Discontinued Pipeline Products 33 Discontinued Pipeline Product Profiles 33 alfadolone 33 indantadol 33 marimastat 33 solimastat 33 V-1003 33 V-158866 34 vipadenant 34 Vernalis Plc - Company Statement 35 Vernalis Plc - Locations And Subsidiaries 37 Head Office 37 8
Other Locations & Subsidiaries 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 38 Disclaimer 39 Read More http://www.idatainsights.com/reports-landing-page.php?id=179162/vernalis-plc-productpipeline-review-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.
9